APA (7th ed.) Citation

Pal, S. K., Bajorin, D., Dizman, N., Hoffman‐Censits, J., Quinn, D. I., Petrylak, D. P., . . . Hoffman-Censits, J. (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer (0008543X), 126(11), 2597. https://doi.org/10.1002/cncr.32806

Chicago Style (17th ed.) Citation

Pal, Sumanta K., et al. "Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association with Comprehensive Genomic Profiling And/or Cell-free DNA Results." Cancer (0008543X) 126, no. 11 (2020): 2597. https://doi.org/10.1002/cncr.32806.

MLA (9th ed.) Citation

Pal, Sumanta K., et al. "Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association with Comprehensive Genomic Profiling And/or Cell-free DNA Results." Cancer (0008543X), vol. 126, no. 11, 2020, p. 2597, https://doi.org/10.1002/cncr.32806.